Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company has demonstrated significant brand channel advantages and is expected to open a second growth curve through its chronic disease O+O model [7] - The company's iHealth brand has gained substantial recognition globally, with products registered in various regions including the Americas, EU, Asia, and Australia [7] - The company is actively expanding its market presence through new retail platforms and e-commerce channels in the domestic market [7] - The O+O model for diabetes care aims to provide comprehensive care services, enhancing treatment efficiency and resource utilization [7] - The financial forecasts for 2025-2027 indicate expected revenues of 28.1 billion, 34.7 billion, and 35.4 billion respectively, with net profits of 14.5 billion, 16.5 billion, and 16.7 billion [7] Financial Summary - Total revenue for 2024 is projected at 25.9 billion, a decrease of 19.77% year-on-year, with a net profit of 16.7 billion, an increase of 33.3% year-on-year [7] - The earnings per share (EPS) for 2024 is estimated at 3.53 yuan, with a price-to-earnings (P/E) ratio of 10.75 [1][8] - The company’s total assets are expected to reach 27.57 billion by 2025, with a debt-to-equity ratio of 18.84% [8]

证券代码：002432 证券简称：九安医疗 天津九安医疗电子股份有限公司 投资者关系活动记录表 | | √特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 √业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 线上参与单位 | 年度暨 年一 网上业绩说明会：通过网络远程方式参加公司"2024 2025 | | 名称及人员姓 | 季度网上业绩说明会"的广大投资者。 | | 名 | 特定对象调研：具体参会机构清单，详见后附"特定调研对象清单"。 | | 时间 | 网上业绩说明会：2025 年 4 月 29 日 15：00-16：00 | | | 特定对象调研：2025 年 4 月 29 日 16：15-17：15 | | 方式 | 网上业绩说明会：网络远程文字方式 | | | 特定对象调研：电话会议方式 | | 上市公司接待 | 董事长、总经理：刘毅 先生 | | | 董事、副总经理：王湧 先生 | | | 董事、副总经理：丛明 先生 | | 人员姓名 | 独立董事：孙卫军 先生 | | | 董事会秘书：邬彤 先生 | | ...